Technology
Health
Pharmaceutical
Zynerba Pharmaceuticals
$5.949876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$5.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.37 (-6.02%) Today
+$0.16 (2.77%) After Hours
Why Robinhood?
You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!
About
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
101.88M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
553.12K
High Today
$6.14
Low Today
$5.66
Open Price
$6.11
Volume
433.15K
52 Week High
$12.50
52 Week Low
$2.75
Collections
Technology
Health
Pharmaceutical
Medical
2015 IPO
US
North America
News
Simply Wall StMar 21
Have Insiders Been Buying Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), you may well want to know whether insiders have been buying or selling. Do Insider Transactions Matter? Most investors know that it is quite permissible for company leaders, such as directors of the ...
Price Paid on Robinhood
11% Lower
Right Now
52 Week Low
$2.75
Average Price Paid
$6.69
52 Week High
$12.50
Earnings
-$0.91
-$0.75
-$0.60
-$0.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.65 per share
Actual
-$0.44 per share